Suggested remit: To appraise the clinical and cost effectiveness of belimumab within its marketing authorisation for treating lupus nephritis.
Status Proposed
Process STA 2018
ID number 2722

Project Team

Project lead Michelle Adhemar

Email enquiries


Key events during the development of the guidance:

Date Update
23 August 2021 (10:00) Scoping workshop
06 July 2021 - 03 August 2021 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance